Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study - Howard, J F, Jr; Utsugisawa, K; Benatar, M; REGAIN Study Group (Lancet Neurol, 2017)
[published correction appears in Lancet Neurol. 2017 Dec;16(12):954]